Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Splenic marginal zone lymphoma.

David Oscier1, Roger Owen, Stephen Johnson

  • 1Department of Haematology, Royal Bournemouth Hospital, Castle Lane East, Bournemouth BH7 7DW, UK. david.oscier@lineone.net

Blood Reviews
|December 2, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Subphenotype of Obesity With Reduced Enteroendocrine Glucagon-Like Peptide 1 Synthesis and Enhanced Tirzepatide Response.

Gastroenterology·2026
Same author

Compositional and functional differences of gut microbiome and metabolome inform pathogenesis of cholestatic liver disease.

Gut microbes·2026
Same author

Microbiome and Vocalization Biomarkers of Infant Distress, Maternal Depression and Parenting Styles.

Chronic stress (Thousand Oaks, Calif.)·2026
Same author

Dietary Nitrate Intake and 16S rRNA-Inferred Nitrite-Generating Capacity of the Subgingival Microbiome May Influence Glucose Metabolism: Results From the Oral Infections Glucose Intolerance and Insulin Resistance Study (ORIGINS).

Journal of clinical periodontology·2025
Same author

Whole genome sequence analysis of <i>Helicobacter pylori</i> isolates reveals incomplete characterization of antimicrobial resistance mechanisms.

iScience·2025
Same author

Description of three new <i>Dryocola</i> species: <i>Dryocola mayonis</i> sp. nov., <i>Dryocola sharpae</i> sp. nov.and <i>Dryocola baronae</i> sp. nov., isolated from human clinical samples.

International journal of systematic and evolutionary microbiology·2025
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Splenic marginal zone lymphoma (SMZL) is a slow-growing B cell cancer affecting the spleen, bone marrow, and blood. Diagnosis involves morphology, immunophenotype, and histology, with chromosome 7q deletions common.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Splenic marginal zone lymphoma (SMZL) is an indolent B cell malignancy.
  • It typically involves the spleen, bone marrow, and blood.
  • Patients may present incidentally or with splenomegaly or anemia.

Purpose of the Study:

  • To review the diagnostic criteria for SMZL.
  • To discuss the genetic abnormalities associated with SMZL.
  • To outline prognostic factors and therapeutic options for SMZL.

Main Methods:

  • Diagnosis relies on lymphocyte morphology, immunophenotype, and histology.
  • Genetic analysis identifies common abnormalities like chromosome 7q deletions.
  • Prognostic factors and treatment strategies are reviewed.

Related Experiment Videos

Main Results:

  • Chromosome 7q deletions occur in 30-50% of SMZL cases.
  • p53 gene alterations are consistently linked to poor outcomes.
  • Median survival is 10-13 years, with transformation to diffuse large cell lymphoma being a cause of death.

Conclusions:

  • SMZL diagnosis requires a multi-faceted approach.
  • Understanding genetic factors and prognostic indicators is crucial for patient management.
  • Therapeutic strategies are varied, aiming to improve survival and prevent transformation.